Directed molecular evolution of an engineered gammaretroviral envelope protein with dual receptor use shows stable maintenance of both receptor specificities

Journal of Virology

Volumn 90, Issue 3, 2016, Pages 1647-1656

  Friis, Kristina Pagh ^a,b   Iturrioz, Xavier ^b,c,d   Thomsen, Jonas ^a   Alvear Perez, Rodrigo ^b,c,d   Bahrami, Shervin ^a,e   Llorens Cortes, Catherine ^b,c,d   Pedersen, Finn Skou ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b INSERM   (France)

^c PSL RESEARCH UNIVERSITY   (France)

^d CNRS   (France)

^e SKAUvaccines   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APELIN RECEPTOR; RECEPTOR; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; XENOTROPIC POLYTROPIC RECEPTOR 1; APLNR PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR; VIRUS RECEPTOR; XENOTROPIC AND POLYTROPIC RETROVIRUS RECEPTOR;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DIRECTED MOLECULAR EVOLUTION; ENZYME SPECIFICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INTERNALIZATION; MOUSE; MURINE LEUKEMIA VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR AFFINITY; VIRAL TROPISM; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS REPLICATION; ANIMAL; CELL LINE; GAMMARETROVIRUS; GENETICS; GENOMIC INSTABILITY; METABOLISM; PHYSIOLOGY;

ANIMALS; CELL LINE; DIRECTED MOLECULAR EVOLUTION; GAMMARETROVIRUS; GENOMIC INSTABILITY; HUMANS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, VIRUS; VIRAL ENVELOPE PROTEINS; VIRAL TROPISM; VIRUS INTERNALIZATION;

EID: 84958093041     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02013-15     Document Type: Article

References (40)

1. Wallin M, Ekstrom M, GaroffH. 2004. Isomerization of the intersubunit disulphide-bond in Env controls retrovirus fusion. EMBO J 23:54-65. http://dx.doi.org/10.1038/sj.emboj.7600012.
2. Wallin M, Ekstrom M, GaroffH. 2005. The fusion-controlling disulfide bond isomerase in retrovirus Env is triggered by protein destabilization. J Virol 79:1678-1685. http://dx.doi.org/10.1128/JVI.79.3.1678-1685.2005.
3. Dutch RE, Jardetzky TS, Lamb RA. 2000. Virus membrane fusion proteins: biological machines that undergo a metamorphosis. Biosci Rep 20: 597-612. http://dx.doi.org/10.1023/A:1010467106305.
4. White JM, Delos SE, Brecher M, Schornberg K. 2008. Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit Rev Biochem Mol Biol 43:189-219. http://dx.doi.org/10.1080/10409230802058320.
5. Kamiyama H, Kakoki K, Yoshii H, Iwao M, Igawa T, Sakai H, Hayashi H, Matsuyama T, Yamamoto N, Kubo Y. 2011. Infection of XC cells by MLVs and Ebola virus is endosome-dependent but acidificationindependent. PLoS One 6:e26180. http://dx.doi.org/10.1371/journal.pone.0026180.
6. Kumar P, Nachagari D, Fields C, Franks J, Albritton LM. 2007. Host cell cathepsins potentiate Moloney murine leukemia virus infection. J Virol 81:10506-10514. http://dx.doi.org/10.1128/JVI.02853-06.
7. Benedict CA, Tun RY, Rubinstein DB, Guillaume T, Cannon PM, Anderson WF. 1999. Targeting retroviral vectors to CD34-expressing cells: binding to CD34 does not catalyze virus-cell fusion. HumGene Ther 10:545-557. http://dx.doi.org/10.1089/10430349950018625.
8. Schnierle BS, Moritz D, Jeschke M, Groner B. 1996. Expression of chimeric envelope proteins in helper cell lines and integration into Moloney murine leukemia virus particles. Gene Ther 3:334-342.
9. Katane M, Takao E, Kubo Y, Fujita R, Amanuma H. 2002. Factors affecting the direct targeting of murine leukemia virus vectors containing peptide ligands in the envelope protein. EMBO Rep 3:899-904. http://dx.doi.org/10.1093/embo-reports/kvf179.
10. Bupp K, Roth MJ. 2002. Altering retroviral tropism using a randomdisplay envelope library. Mol Ther 5:329-335. http://dx.doi.org/10.1006/mthe.2002.0546.
11. Mazari PM, Argaw T, Valdivieso L, Zhang X, Marcucci KT, Salomon DR, Wilson CA, Roth MJ. 2012. Comparison of the convergent receptor utilization of a retargeted feline leukemia virus envelope with a naturallyoccurring porcine endogenous retrovirus A. Virology 427:118-126. http://dx.doi.org/10.1016/j.virol.2012.02.012.
12. Mazari PM, Linder-Basso D, Sarangi A, Chang Y, Roth MJ. 2009. Single-round selection yields a unique retroviral envelope utilizing GPR172A as its host receptor. Proc Natl Acad Sci U S A 106:5848-5853. http://dx.doi.org/10.1073/pnas.0809741106.
13. Sarangi A, Bupp K, Roth MJ. 2007. Identification of a retroviral receptor used by an envelope protein derived by peptide library screening. Proc Natl Acad Sci U S A 104:11032-11037. http://dx.doi.org/10.1073/pnas.0704182104.
14. Li F, Ryu BY, Krueger RL, Heldt SA, Albritton LM. 2012. Targeted entry via somatostatin receptors using a novel modified retrovirus glycoprotein that delivers genes at levels comparable to those of wild-type viral glycoproteins. J Virol 86:373-381. http://dx.doi.org/10.1128/JVI.05411-11.
15. Krueger RL, Albritton LM. 2013. Characteristics of the cellular receptor influence the intracellular fate and efficiency of virus infection. J Virol 87:5916-5925. http://dx.doi.org/10.1128/JVI.00398-13.
16. Bahrami S, Pagh K, Ejegod D, Duch M, Tolstrup M, Pedersen FS. 2012. Construction of a gammaretrovirus with a novel tropism and wild-type replication kinetics capable of using human APJ as an entry receptor. J Virol 86:10621-10627. http://dx.doi.org/10.1128/JVI.01028-12.
17. Galanth C, Hus-Citharel A, Li B, Llorens-Cortes C. 2012. Apelin in the control of body fluid homeostasis and cardiovascular functions. Curr Pharm Des 18:789-798. http://dx.doi.org/10.2174/138161212799277770.
18. O'Carroll AM, Lolait SJ, Harris LE, Pope GR. 2013. The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasis. J Endocrinol 219:R13-35. http://dx.doi.org/10.1530/JOE-13-0227.
19. Choe H, Farzan M, Konkel M, Martin K, Sun Y, Marcon L, Cayabyab M, Berman M, Dorf ME, Gerard N, Gerard C, Sodroski J. 1998. The orphan seven-transmembrane receptor apj supports the entry of primary T-cell-line-tropic and dualtropic human immunodeficiency virus type 1. J Virol 72:6113-6118.
20. Cayabyab M, Hinuma S, Farzan M, Choe H, Fukusumi S, Kitada C, Nishizawa N, Hosoya M, Nishimura O, Messele T, Pollakis G, Goudsmit J, Fujino M, Sodroski J. 2000. Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry. J Virol 74:11972-11976. http://dx.doi.org/10.1128/JVI.74.24.11972-11976.2000.
21. Fan X, Zhou N, Zhang X, Mukhtar M, Lu Z, Fang J, DuBois GC, Pomerantz RJ. 2003. Structural and functional study of the apelin-13 peptide, an endogenous ligand of the HIV-1 coreceptor, APJ. Biochemistry 42:10163-10168. http://dx.doi.org/10.1021/bi030049s.
22. Lee DK, Ferguson SS, George SR, O'Dowd BF. 2010. The fate of the internalized apelin receptor is determined by different isoforms of apelin mediating differential interaction with beta-arrestin. Biochem Biophys Res Commun 395:185-189. http://dx.doi.org/10.1016/j.bbrc.2010.03.151.
23. Iturrioz X, Gerbier R, Leroux V, Alvear-Perez R, Maigret B, Llorens-Cortes C. 2010. By interacting with the C-terminal Phe of apelin, Phe255 and Trp259 in helix VI of the apelin receptor are critical for internalization. J Biol Chem 285:32627-32637. http://dx.doi.org/10.1074/jbc. M110.127167.
24. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, Kurokawa T, Onda H, Fujino M. 1998. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 251:471-476. http://dx.doi.org/10.1006/bbrc.1998.9489.
25. Iturrioz X, Alvear-Perez R, De Mota N, Franchet C, Guillier F, Leroux V, Dabire H, Le Jouan M, Chabane H, Gerbier R, Bonnet D, Berdeaux A, Maigret B, Galzi JL, Hibert M, Llorens-Cortes C. 2010. Identification and pharmacological properties of E339-3D6, the first nonpeptidic apelin receptor agonist. FASEB J 24:1506-1517. http://dx.doi.org/10.1096/fj.09-140715.
26. El Messari S, Iturrioz X, Fassot C, De Mota N, Roesch D, Llorens-Cortes C. 2004. Functional dissociation of apelin receptor signaling and endocytosis: implications for the effects of apelin on arterial blood pressure. J Neurochem 90:1290-1301. http://dx.doi.org/10.1111/j.1471-4159.2004.02591.x.
27. Murza A, Parent A, Besserer-Offroy E, Tremblay H, Karadereye F, Beaudet N, Leduc R, Sarret P, Marsault E. 2012. Elucidation of the structure-activity relationships of apelin: influence of unnatural amino acids on binding, signaling, and plasma stability. ChemMedChem 7:318-325. http://dx.doi.org/10.1002/cmdc.201100492.
28. Bahrami S, Duch M, Pedersen FS. 2007. Ligand presentation on a synthetic flexible hinge in Moloney murine leukemia virus SU supports entry via a heterologous receptor. Virology 363:303-309. http://dx.doi.org/10.1016/j.virol.2007.01.021.
29. Zavorotinskaya T, Albritton LM. 1999. Suppression of a fusion defect by second site mutations in the ecotropic murine leukemia virus surface protein. J Virol 73:5034-5042.
30. Ferrarone J, Knoper RC, Li R, Kozak CA. 2012. Second site mutation in the virus envelope expands the host range of a cytopathic variant of Moloney murine leukemia virus. Virology 433:7-11. http://dx.doi.org/10.1016/j.virol.2012.06.031.
31. Albericio F, Annis I, Royo M, Barany G. 2000. Preparation and handling of peptides containing methionine and cysteine, p 77-114. In Chan WC, White PD (ed), Fmoc solid phase peptide synthesis. A practical approach. Oxford University Press, Oxford, United Kingdom.
32. De Mota N, Lenkei Z, Llorens-Cortes C. 2000. Cloning, pharmacological characterization and brain distribution of the rat apelin receptor. Neuroendocrinology 72:400-407. http://dx.doi.org/10.1159/000054609.
33. Bahrami S, Jespersen T, Pedersen FS, Duch M. 2003. Mutational library analysis of selected amino acids in the receptor binding domain of envelope of Akv murine leukemia virus by conditionally replicationcompetent bicistronic vectors. Gene 315:51-61. http://dx.doi.org/10.1016/S0378-1119(03)00719-4.
34. Evans LH, Morrison RP, Malik FG, Portis J, Britt WJ. 1990. A neutralizable epitope common to the envelope glycoproteins of ecotropic, polytropic, xenotropic, and amphotropic murine leukemia viruses. J Virol 64:6176-6183.
35. 2+, contributes to the substrate specificity of aminopeptidase A. Biochemistry 39:3061-3068. http://dx.doi.org/10.1021/bi9925726.
36. Medhurst AD, Jennings CA, Robbins MJ, Davis RP, Ellis C, Winborn KY, Lawrie KW, Hervieu G, Riley G, Bolaky JE, Herrity NC, Murdock P, Darker JG. 2003. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem 84:1162-1172. http://dx.doi.org/10.1046/j.1471-4159.2003.01587.x.
37. Zhang Y, Maitra R, Harris DL, Dhungana S, Snyder R, Runyon SP. 2014. Identifying structural determinants of potency for analogs of apelin-13: integration of C-terminal truncation with structureactivity. Bioorg Med Chem 22:2992-2997. http://dx.doi.org/10.1016/j.bmc.2014.04.001.
38. Bahrami S, Duch M, Pedersen FS. 2004. Change of tropism of SL3-2 murine leukemia virus, using random mutational libraries. J Virol 78: 9343-9351. http://dx.doi.org/10.1128/JVI.78.17.9343-9351.2004.
39. Zhou N, Fan X, Mukhtar M, Fang J, Patel CA, DuBois GC, Pomerantz RJ. 2003. Cell-cell fusion and internalization of the CNS-based, HIV-1 co-receptor, APJ. Virology 307:22-36. http://dx.doi.org/10.1016/S0042-6822(02)00021-1.
40. Miyakawa K, Fujita R, Katane M, Kubo Y, Amanuma H. 2008. Effects of the ligand sequence modifications on the retargeted transduction by the retroviral vector having a ligand-chimeric Env protein. J Gen Virol 89: 3137-3143. http://dx.doi.org/10.1099/vir.0.2008/006031-0.